Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
⏸️ Investing
5 Stocks slammed on the ASX today
⏸️ Investing
The 4 best companies to buy for your children in 2015
⏸️ Investing
The 4 best value stocks to buy with $10,000 in 2015
⏸️ Investing
4 terrifyingly cheap companies to buy this Halloween
⏸️ Investing
Invest like Peter Lynch with these 3 ASX stocks
⏸️ Investing
Is this the best value healthcare stock that nobody is talking about?
⏸️ Best ASX Shares
Here's why the current earnings season is a defining moment for small and microcap stocks
⏸️ Investing
2 pharmaceutical stocks growing sales in the giant US drug market – should you buy?
⏸️ Investing
Your instant 6-share biotech portfolio
⏸️ Investing
Mayne Pharma Group half-year update points to 20% revenue rise
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
